The role of vitamin D for inflammatory bowel diseases

Authors: T. Hlavatý;  A. Krajčovičová;  J. Payer
Authors‘ workplace: Gastroenterologické a hepatologické oddelenie, V. interná klinika LF UK a UN Bratislava
Published in: Gastroent Hepatol 2012; 66(1): 37-43
Category: IBD: Review Article


Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) most frequently affecting young patients. The aetiopathogenesis of IBD remains unclear. Without understanding the causes of IBD, causal treatment cannot be known and therapy is based on chronic immunosuppresion, which entails considerable side effects and financial costs. Vitamin D is a hormonally active vitamin with strong immunomodulatory effects. The high prevalence of IBD in northern Europe and the USA, genetic association studies and, especially, the results of experimental studies on animals indicate the significant role of VD in the aetiopathogenesis of IBD. Vitamin D supplementation and the saturation of the organism with 25(OH)D3 reserves might represent a novel approach to the treatment of IBD that could be simple, effective, safe and cheap.

Key words:
inflammatory bowel disease – IBD – Crohn’s disease – ulcerative colitis – vitamin D – pathogenesis – therapy


1. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991; 100(1): 143–149.

2. Andreassen H, Rix M, Brot C et al. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand J Gastroenterol 1998; 33(6): 1087–1093.

3. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26(5): 662–687.

4. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80 (6 Suppl): 1678S–1688S.

5. Ross CA, Taylor CL, Yaktine AK et al. Dietary reference intakes for calcium and vitamin D. The National Academies Press 2011.

6. Kimball SM, Ursell MR, O'Connor P et al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutrition 2007; 86(3): 645–651.

7. Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol 2010; 121(1–2): 297–300.

8. Rucker D, Allan JA, Fick GH et al. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002; 166(12): 1517–1524.

9. Looker AC, Dawson-Hughes B, Calvo MS et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30(5): 771–777.

10. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 2002; 76(1): 187–192.

11. Holick MF, Siris ES, Binkley N et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90(6): 3215–3224.

12. Hintzpeter B, Mensink GBM, Thierfelder W et al. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008; 62(9): 1079–1089.

13. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004; 89–90(1): 611–614.

14. Dawson-Hughes B, Heaney R, Holick M et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16(7): 713–716.

15. Lips P, Chapuy MC, Dawson-Hughes B et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9(5): 394–397.

16. Carter GD, Carter CR, Gunter E et al. Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 2004; 89–90(1): 467–471.

17. Binkley N, Krueger D, Cowgill CS et al. Assay Variation Confounds the Diagnosis of Hypovitaminosis D: A Call for Standardization. J Clin Endocrinol Metab 2004; 89(7): 3152–3157.

18. Hollis BW. Comparison of Commercially Available 125I-based RIA Methods for the Determination of Circulating 25-Hydroxyvitamin D. Clin Chem 2000; 46(10): 1657–1661.

19. Carter GD, Carter R, Jones J et al. How Accurate Are Assays for 25-Hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme. Clin Chem 2004; 50(11): 2195–2197.

20. Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr 2008; 88(2): 500S–506S.

21. Binkley N, Novotny R, Krueger D et al. Low Vitamin D Status despite Abundant Sun Exposure. J Clin Endocrin Metab 2007; 92(6): 2130–2135.

22. Gloth FM 3rd, Gundberg CM, Hollis BW et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995; 274(21): 1683–1686.

23. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351(9105): 805–806.

24. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338(12): 777–783.

25. Tangpricha V, Pearce EN, Chen TC et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112(8): 659–662.

26. Lips P, Duong T, Oleksik A et al. A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial. J Clin Endocrin Metab 2001; 86(3): 1212–1221.

27. Sullivan SS, Rosen CJ, Halteman WA et al. Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc 2005; 105(6): 971–974.

28. Jahnsen J, Falch JA, Mowinckel P et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37(2): 192–199.

29. Sentongo TA, Semaeo EJ, Stettler N et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002; 76(5): 1077–1081.

30. Kuwabara A, Tanaka K, Tsugawa N et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporosis International 2009; 20(6): 935–942.

31. Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D Status in Children and Young Adults With Inflammatory Bowel Disease. Pediatrics 2006; 118(5): 1950–1961.

32. Souza HNd, Lora FLg, Kulak CAM et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol 2008; 52(4): 684–691.

33. Bours P, Wielders J, Vermeijden J et al. Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease. Osteoporos Int 2010; 22(11): 2857–2867.

34. McCarthy D, Duggan P, O'Brien M et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 2005; 21(9): 1073–1083.

35. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr 2006; 60(7): 889–896.

36. Stumpf WE, Sar M, Reid FA et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206(4423): 1188–1190.

37. Kreutz M, Andreesen R, Krause SW et al. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 1993; 82(4): 1300–1307.

38. Miyaura C, Abe E, Nomura H et al. 1 alpha,25-Dihydroxyvitamin D3 suppresses proliferation of murine granulocyte-macrophage progenitor cells (CFU-C). Biochem Biophys Res Commun 1982; 108(4): 1728–1733.

39. Koeffler HP. Vitamin D: myeloid differentiation and proliferation. Haematol Blood Transfus 1985; 29: 409–417.

40. Tanaka H, Abe E, Miyaura C et al. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). The presence of a cytosol receptor and induction of differentiation. Biochem Biophys Res Commun 1983; 117(1): 86–92.

41. Tsoukas CD, Watry D, Escobar SS et al. Inhibition of Interleukin-1 Production by 1,25-Dihydroxyvitamin D3. J Clin Endocrin Metab 1989; 69(1): 127–133.

42. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984; 224(4656): 1438–1440.

43. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987; 253(6): E675–E683.

44. Smith EL, Pincus SH, Donovan L et al. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J Am Acad Dermatol 1988; 19(3): 516–528.

45. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93(15): 7861–7864.

46. Cantorna MT, Munsick C, Bemiss C et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130(11): 2648–2652.

47. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223(3): 230–233.

48. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8(4): 174–179.

49. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol Inhibits the Progression of Arthritis in Murine Models of Human Arthritis. J Nutrition 1998; 128(1): 68–72.

50. Barrat FJ, Cua DJ, Boonstra A et al. In Vitro Generation of Interleukin 10 producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1) and Th2-inducing Cytokines. J Exp Med 2002; 128(1): 603–616.

51. Gregori S, Giarratana N, Smiroldo S et al. A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice. Diabetes 2002; 51(5): 1367–1374.

52. Andjelkovic Z, Vojinovic J, Pejnovic N et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17(4): 453–456.

53. Yahav S, Buffenstein R. Cholecalciferol supplementation alters gut function and improves digestibility in an underground inhabitant, the naked mole rat (Heterocephalus glaber), when fed on a carrot diet. Br J Nutr 1993; 69(1): 233–241.

54. Kühn R, Löhler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75(2): 263–274.

55. Froicu M, Weaver V, Wynn TA et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17(12): 2386–2392.

56. Yu S, Bruce D, Froicu M et al. Failure of T cell homing, reduced CD4/CD8αα intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. PNAS 2008; 105(52): 20834–20839.

57. Zhu Y, Mahon BD, Froicu M et al. Calcium and 1α,25-dihydroxyvitamin D3 target the TNF-α pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35(1): 217–224.

58. Pedersen AE, Schmidt EGW, Gad M et al. Dexamethasone/1α-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model. Immunology 2009;127(3): 354–64.

59. Kong J, Zhang Z, Musch MW et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294(1): G208–G216.

60. Paz HB, Tisdale AS, Danjo Y et al. The role of calcium in mucin packaging within goblet cells. Experimental Eye Research 2003; 77(1): 69–75.

61. Wu S, Liao AP, Xia Y et al. Vitamin D Receptor Negatively Regulates Bacterial-Stimulated NF-ÎşB Activity in Intestine. Am J Pathol 2010; 177(2): 686–697.

62. Peyrin-Biroulet L, Oussalah A, Bigard M-A. Crohn's disease: The hot hypothesis. Med Hypotheses 2009; 73(1): 94–96.

63. Simmons JD, Mullighan C, Welsh KI et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000; 47(2): 211–214.

64. Naderi N, Farnood A, Habibi M et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23(12): 1816–1822.

65. Dresner-Pollak R, Ackerman Z, Eliakim R, et al. The BsmI Vitamin D Receptor Gene Polymorphism Is Associated with Ulcerative Colitis in Jewish Ashkenazi Patients. Genet Test 2004;8(4):417-20.

66. Joseph AJ, George B, Pulimood AB et al. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res 2009; 130(1): 133–137.

67. Lewis JD, Aberra FN, Lichtenstein GR et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126(3): 665–673.

68. Cantorna MT, Hullett DA, Redaelli C et al. 1,25-Dihydroxyvitamin D3 Prolongs Graft Survival Without Compromising Host Resistance To Infection or Bone Mineral Density. Transplant 1998; 66(7): 828–831.

69. Hullett DA, Cantorna MT, Redaelli C et al. Prolongation of Allograft Survival By 1,25-Dihydroxyvitamin D. Transplantation 1998; 66(7): 824–828.

70. Thomas MG, Nugent KP, Forbes A et al. Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis. Gut 1994; 35(12): 1718–1720.

71. Stio M, Bonanomi AG, d'Albasio G et al. Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 2001; 61(3): 365–371.

72. Miheller P, Műzes G, Hritz I et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15(11): 1656–1662.

73. Koutkia P, Lu Z, Chen TC et al. Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation. Gastroenterology 2001; 121(6): 1485–1488.

74. Leventis P, Kiely PDW. The tolerability and biochemical effects of high dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scan J Rheumatology 2009; 38(2): 149–153.

75. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med 2004; 95(6): 468–480.

76. Schoon EJ, van Nunen AB, Wouters RSME et al. Osteopenia and Osteoporosis in Crohn's Disease: Prevalence in a Dutch Population-based Cohort. Scand J Gastroenterol 2000; 35 (Suppl): 43.

77. Farraye FA, Odze RD, Eaden J et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138(2): 738–745.

78. Byers S, Rowlands T, Beildeck M et al. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 2011 [Epub ahead of print].

79. Touvier M, Chan DSM, Lau R et al. Meta-Analyses of Vitamin D Intake, 25-Hydroxyvitamin D Status, Vitamin D Receptor Polymorphisms, and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev 2011; 20(5): 1003–1016.

Paediatric gastroenterology Gastroenterology and hepatology Surgery

Article was published in

Gastroenterology and Hepatology

Issue 1

2012 Issue 1

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account